FDA Says No to Regulating CBD Products as Supplements
How to regulate CBD supplements has become a pressing public health concern as the popularity of CBD supplements has exploded in the United States
Diagnosis & Disease Information
Abbott’s SCS System Cleared for Patients With Painful Diabetic Peripheral Neuropathy
It was originally approved in 2019 for the treatment of chronic pain.
FDA Greenlights Ibuprofen Oral Suspension Compounding to Help With Hospital Supply
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
Rate of Opioid Rx at Discharge From Emergency Department Declining
Decrease seen in rate and percentage of emergency department visits with opioid prescribed at discharge from 2017-2018 to 2019-2020
Recommendations Developed for Managing Neuromuscular Blockade
Authors recommend against clinical assessment alone when neuromuscular drugs are administered due to insensitivity of assessment
Postoperative Restrictive Opioid Rx Protocol Feasible for Most Patients
Significant decreases seen in the number of opioids prescribed, conversion to long-term opioid use seen
Diclofenac Epolamine Topical System, a Generic of Flector, Now Available
Diclofenac epolamine topical system is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Noninvasive Interventions Can Reduce Spine Pain Versus Usual Care
Small reductions in pain-related disability at three months for multidisciplinary biopsychosocial intervention, individualized postural therapy
Sublingual Buprenorphine/Naloxone Tied to More Adverse Dental Outcomes
More adverse dental outcomes seen with sublingual buprenorphine/naloxone compared with use of transdermal buprenorphine or oral naltrexone
Buprenorphine Extended-Release SC Injection Under Review Again for Opioid Use Disorder
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.
